I. Executive Summary and Investment Thesis The Core Problem The generic drug industry saves the U.S. healthcare system roughly $216 […]

Partnering with a Contract Development and Manufacturing Organization (CDMO) is no longer a simple procurement exercise. It is a fundamental

1. Executive Summary and Key Takeaways The FDA’s Product-Specific Guidance (PSG) program is now the most consequential publicly available dataset

The complete 2025 playbook for generic drug development strategy: Paragraph IV mechanics, complex generics IP moats, biosimilar development roadmaps, IRA

The global pharmaceutical landscape is undergoing a tectonic shift, and at its epicenter lies India. Long celebrated as the “Pharmacy

Amgen’s Amjevita became the first U.S. Humira biosimilar on January 31, 2023. Within twelve months, eleven additional adalimumab biosimilars had

The U.S. generic drug market generates roughly $120 billion in annual revenue and absorbs more than 90% of all dispensed

The traditional patent bargain—a 20-year monopoly in exchange for public disclosure—has transitioned into a sophisticated system of legal layering. In

How to attack weak patents, fortify your portfolio, and turn every validity challenge into a competitive lever — across the